At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 234 enrolled
Drug / intervention
Peramivir +1 moredrug
Likely dose
Peramivir 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Infection
In Brief
A Phase 3 clinical trial evaluating Peramivir for Seasonal Influenza and 6 related conditions. Completed, enrolled 234 participants across 110 sites in 6 countries.
Detailed Summary
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza, Cough, Sore Throat, Nasal Congestion, Myalgia, Headache, Fatigue
CountriesAustralia, Canada, Mexico, New Zealand, Puerto Rico, United States
CollaboratorsDepartment of Health and Human Services
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartOct 2009
Primary CompletionOct 2010
Study CompletionAug 2011
TodayJul 2026
First PostedAug 13, 2009
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2010
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.9 years ago
Interventions
Peramivirdrug
300 mg twice daily
Peramivirdrug
600 mg once daily